EMEA-001196-PIP02-17
Key facts
| Active substance |
Fostamatinib
|
| Therapeutic area |
Other
|
| Decision number |
P/0195/2018
|
| PIP number |
EMEA-001196-PIP02-17
|
| Pharmaceutical form(s) |
Film-coated tablet
|
| Condition(s) / indication(s) |
Treatment of idiopathic thrombocytopenic purpura as a model for immunomodulation
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Rigel Pharmaceuticals Ltd
E-mail: dvance@rigel.com |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|